Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

<p><strong>Background:</strong> Trastuzumab targets the extracellular domain of the HER2 protein. Adding trastuzumab to chemotherapy for patients with early-stage, HER2-positive breast cancer reduces the risk of recurrence and death, but is associated with cardiac toxicity. We inve...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsman: Early Breast Cancer Trialists’ Collaborative group (EBCTCG)
Övriga upphovsmän: Bradley, R
Materialtyp: Journal article
Språk:English
Publicerad: Elsevier 2021